|
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma Clinical research trials and CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma. CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma clinical trial. Human subjects frequently get the finest healthcare available for their CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma
For Condition: Multiple Myeloma
Status: No longer recruiting
Sponsor(s): Celgene Corporation , PharmaNet
Synopsis: Randomized subjects will receive CC-5013 plus high-dose dexamethasone or identically appearing placebo to CC-5013 plus high-dose dexamethasone, in 4-week cycles. For each subject the study will consist of a treatment phase and a follow-up phase.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma. - No more than 3 previous anti-myeloma regimens - No high-dose dexamethasone (total monthly dose of dexamethasone greater than 200 mg) within 6 months of study randomization. - Measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample). Exclusion Criteria: - Prior development of disease progression during high-dose dexamethasone containing therapy. - Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm cubed - Laboratory abnormalities: Platelet count less than 75,000/mm cubed - Laboratory abnormalities: Serum creatinine greater than 2.5 mg/dL - Laboratory abnormalities: Serum SGOT/AST or SGPT/ALT greater than 3.0 x upper limit of normal - Laboratory abnormalities: Serum total bilirubin greater than 2.0 mg/dL - Prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for greater than or equal to 5 years. - Known hypersensitivity to thalidomide or dexamethasone. - The development of a desquamating rash while taking thalidomide.
Total Enrollment: 302
Location and Contact Information:
UCLA School of Medicine
Los Angeles, California, 90095
United States
Roswell Park Cancer Institute
Buffalo, New York, 14263
United States
New York Presbyterian Hospital
New York City, New York, 10021
United States
H Lee Moffitt Cancer Center
Tampa, Florida, 33612-9497
United States
Emory University
Atlanta, Georgia, 30322
United States
Dalhousie University
Halifax, Nova Scotia, B3H2Y9
Canada
University of Miami
Miami, Florida, 33136
United States
Yale University School of Medicine
New Haven, Connecticut, 06520
United States
Charleston Hematology/Oncology P.A.
Charleston, South Carolina, 29403
United States
Sarah Cannon Cancer Center
Nashville, Tennessee, 37203-1632
United States
UCSF California
San Francisco, California, 94143
United States
Clinical Research Consultants, Inc.
Hoover, Alabama, 35216
United States
Indiana Cancer Research Institute
Indianapolis, Indiana, 46202-5254
United States
MBCCOP Our Lady of Mercy Cancer Center New York Medical College
Bronx, New York, 10466
United States
Duke University Medical Center
Durham, North Carolina, 27710
United States
City of Hope National Medical Center
Duarte, California, 91010
United States
Stanford University Medical Center, Division of Hematology
Stanford, California, 94305-5112
United States
McGill University
Montreal, Quebec, PQH2W1S6
Canada
University of Florida
Gainesville, Florida, 32610
United States
Mayo Clinic- Jacksonville
Jacksonville, Florida, 32224
United States
Rush Cancer Institute Section of Hematology
Chicago, Illinois, 60612-3824
United States
University Of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109
United States
Oncology Hematology Consultants
Sarasota, Florida, 34239
United States
Medical University of SC
Charleston, South Carolina, 29425
United States
Kaiser Permanente Northwest Region Center for Health Research
Portland, Oregon, 97227
United States
MD Anderson Cancer Center
Houston, Texas, 77030-4009
United States
Johns Hopkins Medicine Department of Oncology
Baltimore, Maryland, 21231
United States
St. Vincent's Comprehensive Cancer Center
New York City, New York, 10011
United States
University of Iowa Hospital Clinic
Iowa City, Iowa, 52242
United States
Washington University School of Medicine- Sherman Cancer Center
St. Louis, Missouri, 63110
United States
SUNY Upstate Medical University
Syracuse, New York, 13210
United States
Cleveland Clinic Myeloma Program
Cleveland, Ohio, 44195
United States
Medical College of Georgia
Augusta, Georgia, 30912-3125
United States
Hospital Charles LeMoyne
Greenfield Park, Quebec, J4V2H1
Canada
South Carolina Oncology Group
West Columbia, South Carolina, 29169
United States
Princess Margaret Hospital
Toronto, Ontario, M5J2M9
Canada
Ocshner Clinical Foundation
New Orleans, Louisiana, 70121
United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02115
United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601
United States
Cross Cancer Institute
Edmonton, Alberta, T6G1Z2
Canada
Froedtert Hospital/BMT Medical College of Wisconsin
Milwaukee, Wisconsin, 53226-3522
United States
Wake Forest University School of Medicine
Winston Salem, North Carolina, 27157-1023
United States
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
United States
Northwestern University Med Ctr
Chicago, Illinois, 60611-2927
United States
Dana Farber Cancer Institute
Boston, Massachusetts, 02115
United States
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213
United States
Karmanos Cancer Institute
Detroit, Michigan, 48201
United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104
United States
Loyola University Medical Center
Maywood, Illinois, 60153
United States
Ohio State University
Columbus, Ohio, 43210
United States
Additional Information:
Study ID Numbers: CC-5013-MM-009;
Study Start Date: January 2003
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00056160
Other Multiple Myeloma Studies:
1. Comparison of Antibody Therapies in Treating Patients With Graft- Versus-Host Disease That Does Not Respond to Steroid Therapy
2. Evaluation of Cellular and Humoral Immunity Against the Idiotype in Multiple Myeloma Patients Undergoing Autologous Transplantation After Idiotype Vaccination in an Attempt to Decrease the Risk of Relapse
3. Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants
4. Study of Combination PS-341 and Thalidomide in Multiple Myeloma
5. Xcellerated T CellsTM in Patients with Multiple Myeloma
Related Studies:
Other Multiple Myeloma Clinical Trials
Other Florida Clinical Trials
Other Jacksonville Clinical Trials
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects with Multiple Myeloma
|
|
|
|
|
|
|
|